| International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma WD Travis, E Brambilla, M Noguchi, AG Nicholson, KR Geisinger, ... Journal of thoracic oncology 6 (2), 244-285, 2011 | 5888 | 2011 |
| Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain W Pao, VA Miller, KA Politi, GJ Riely, R Somwar, MF Zakowski, MG Kris, ... PLoS medicine 2 (3), 225, 2005 | 4273 | 2005 |
| Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer AT Shaw, DW Kim, K Nakagawa, T Seto, L Crinó, MJ Ahn, T De Pas, ... New England Journal of Medicine 368 (25), 2385-2394, 2013 | 4020 | 2013 |
| Tumor mutational load predicts survival after immunotherapy across multiple cancer types RM Samstein, CH Lee, AN Shoushtari, MD Hellmann, R Shen, ... Nature genetics 51 (2), 202-206, 2019 | 3061 | 2019 |
| Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients A Zehir, R Benayed, RH Shah, A Syed, S Middha, HR Kim, P Srinivasan, ... Nature medicine 23 (6), 703-713, 2017 | 2908 | 2017 |
| Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers HA Yu, ME Arcila, N Rekhtman, CS Sima, MF Zakowski, W Pao, MG Kris, ... Clinical cancer research 19 (8), 2240-2247, 2013 | 2586 | 2013 |
| Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer AT Shaw, SHI Ou, YJ Bang, DR Camidge, BJ Solomon, R Salgia, GJ Riely, ... New England Journal of Medicine 371 (21), 1963-1971, 2014 | 2115 | 2014 |
| MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib J Bean, C Brennan, JY Shih, G Riely, A Viale, L Wang, D Chitale, N Motoi, ... Proceedings of the National Academy of Sciences 104 (52), 20932-20937, 2007 | 1947 | 2007 |
| KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib W Pao, TY Wang, GJ Riely, VA Miller, Q Pan, M Ladanyi, MF Zakowski, ... PLoS medicine 2 (1), e17, 2005 | 1937 | 2005 |
| OncoKB: a precision oncology knowledge base D Chakravarty, J Gao, S Phillips, R Kundra, H Zhang, J Wang, ... JCO precision oncology 1, 1-16, 2017 | 1925 | 2017 |
| Ceritinib in ALK-Rearranged Non–Small-Cell Lung Cancer AT Shaw, DW Kim, R Mehra, DSW Tan, E Felip, LQM Chow, DR Camidge, ... New England Journal of Medicine 370 (13), 1189-1197, 2014 | 1823 | 2014 |
| Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study NM Kuderer, TK Choueiri, DP Shah, Y Shyr, SM Rubinstein, DR Rivera, ... The Lancet 395 (10241), 1907-1918, 2020 | 1814 | 2020 |
| Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study DR Camidge, YJ Bang, EL Kwak, AJ Iafrate, M Varella-Garcia, SB Fox, ... The lancet oncology 13 (10), 1011-1019, 2012 | 1535 | 2012 |
| Molecular determinants of response to anti–programmed cell death (PD)-1 and anti–programmed death-ligand 1 (PD-L1) blockade in patients with non–small-cell lung cancer profiled … H Rizvi, F Sanchez-Vega, K La, W Chatila, P Jonsson, D Halpenny, ... Journal of clinical oncology 36 (7), 633, 2018 | 1221 | 2018 |
| Non–small cell lung cancer, version 5.2017, NCCN clinical practice guidelines in oncology DS Ettinger, DE Wood, DL Aisner, W Akerley, J Bauman, LR Chirieac, ... Journal of the National Comprehensive Cancer Network 15 (4), 504-535, 2017 | 1181 | 2017 |
| Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis AT Shaw, BY Yeap, BJ Solomon, GJ Riely, J Gainor, JA Engelman, ... The lancet oncology 12 (11), 1004-1012, 2011 | 1134 | 2011 |
| Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases A Yoshizawa, N Motoi, GJ Riely, CS Sima, WL Gerald, MG Kris, BJ Park, ... Modern pathology 24 (5), 653-664, 2011 | 1062 | 2011 |
| Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor–mutant lung adenocarcinomas with acquired resistance to kinase inhibitors MN Balak, Y Gong, GJ Riely, R Somwar, AR Li, MF Zakowski, A Chiang, ... Clinical cancer research 12 (21), 6494-6501, 2006 | 969 | 2006 |
| Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non–small-cell lung cancer D Jackman, W Pao, GJ Riely, JA Engelman, MG Kris, PA Jänne, T Lynch, ... Journal of clinical oncology 28 (2), 357, 2010 | 954 | 2010 |
| Impact of baseline steroids on efficacy of programmed cell death-1 and programmed death-ligand 1 blockade in patients with non-small-cell lung cancer KC Arbour, L Mezquita, N Long, H Rizvi, E Auclin, A Ni, G Martínez-Bernal, ... Journal of Clinical Oncology 36 (28), 2872-2878, 2018 | 865 | 2018 |
